It was a nightmare. We were basically forced to use Eclipse (instead of IntelliJ which everybody was accustomed to). Eclipse alone was a nightmare to use (slow, imports not founds, etc).

On the OSGi side:

There is no package manager. One team tried to set up maven but they failed. We just loaded jars.

The manifest files were a mess. Eclipse launch configurations were a mess (had to be re-imported after any change).

A small project which only required a backend was needlessly split into 5 parts. Over-engineering at its finest.

Creating the 10000th Conways Game of Life? Developing some crappy game on my own? No, thanks.

Developing something for an existing game? That would have been great! I'm all with you.

I can't get a polish SIM card and use it for an entire year in Germany, for example.

It exists.

If you gave to answer "it depends" on a "was ist ever", you should have written "yes" instead, imo.

About 500€ per year less than without this app. So yeah, for that price they can track me anytime I drive, I don't have an issue with that.

I doubt regular manufacturers would have begun releasing real EV cars without their pressure.

what? In the times where 15 people have phone dailies/dailys?

Most Germans have a girocard, way less hava got a debit/credit card.

https://www.tide.co/blog/a-card-designed-around-you

Bonus weirdness for tide cards: Name, credit card number, signature and cvv are all on the back, haha

Some Bank in Spain gives out vertical cards too, someone I know has one.

> Until data from well-designed clinical trials are available and reliable, and standardized CBD products that are produced using GMP are available, caution must be exercised in any consideration of using CBD for the treatment of epilepsy. In the meantime, based upon promising preliminary data, further clinical research should be wholeheartedly pursued.

Citing a part of the second paper's Conclusion:

> Human experimental findings support preclinical findings, and also suggest a lack of anxiogenic effects, minimal sedative effects, and an excellent safety profile. Current preclinical and human findings mostly involve acute CBD dosing in healthy subjects, so further studies are required to establish whether chronic dosing of CBD has similar effects in relevant clinical populations. Overall, this review emphasizes the potential value and need for further study of CBD in the treatment of anxiety disorders.

So the second one says it seems good for acute dosing. Both say more research has to be done. Let's hope this is being done in the near future.

My mum was mad at me for paying for 1 day shipping (eg Prime Delivery - 20€ in Spain - crazy cheap) because "You know that this won't work in Spain!!"